GlassScriptPhysician profile
Brian William Hanrahan
NPI 1093920449
$1,147.69
in general payments reported to CMS, 2019-2025
23 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $32.46 · 2021: $61.58 · 2022: $42.42 · 2023: $112 · 2024: $430 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,011.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $284.18 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $164.81 | 2020-2023 | Xarelto |
| Pfizer INC. | $85.57 | 2024 | |
| Lilly USA, LLC | $77.40 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.64 | 2025 | Xifaxan |
| Amgen INC. | $56.35 | 2024-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $42.85 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $42.79 | 2024-2025 | Breztri, Airsupra |
| Novo Nordisk INC | $41.26 | 2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.97 | 2023-2024 | Jardiance |
| Lundbeck LLC | $34.12 | 2024-2025 | Rexulti |
| Edwards Lifesciences Corporation | $32.20 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $24.58 | 2025 | General - Pain Management |
| Sumitomo Pharma America, INC. | $20.03 | 2025 | Gemtesa |
| Abbott Laboratories | $19.37 | 2023 | Amplatzer Amulet |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $18.80 | 2025 | Trintellix |
| Esperion Therapeutics, INC. | $17.97 | 2024 | Nexletol |
| Ardelyx, INC. | $17.06 | 2024 | Ibsrela |
| Actelion Pharmaceuticals US, INC. | $15.06 | 2025 | Uptravi, Opsumit |
| Philips North America LLC | $14.89 | 2024 | (Ck6) Holter |
| Glaxosmithkline, LLC. | $14.41 | 2025 | Arexvy, Shingrix |
| Watermark Medical, INC. | $13.92 | 2024 | |
| Abiomed | $13.46 | 2024 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hanrahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.